<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34949141</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>7-8</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures.</ArticleTitle><Pagination><StartPage>500</StartPage><EndPage>507</EndPage><MedlinePgn>500-507</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.2016838</ELocationID><Abstract><AbstractText><i>Objective:</i> Uniform data collection is fundamental for multicentre clinical trials. We aim to determine the variability, between ALS trial centers, in the prevalence of unexpected or implausible improvements in the revised ALS functional rating scale (ALSFRS-R) score, and its associations with individual patient and item characteristics.<i>Methods:</i> We used data from two multicentre studies to estimate the prevalence of an unexpected increase or implausible improvement in the ALSFRS-R score, defined as an increase of 5 points or more between two consecutive, monthly visits. For each patient with a 5-point or more increase, we evaluated the individual contribution of each ALSFRS-R item.<i>Results:</i> Longitudinal ALSFRS-R scores, originating from 114 trial centers enrolling a total of 1,240 patients, were analyzed. A 5-point or more increase in ALSFRS-R total score was found in 151 (12.2%) patients, with prevalence per study center ranging from 0% to 83%. Bulbar onset, faster disease progression at enrollment, and a lower ALSFRS-R score at baseline were associated with a sudden 5-point or more increase in the ALSFRS-R total score. ALSFRS-R items 2 (saliva), 9 (stairs), 10 (dyspnea), and 11 (orthopnea) were the primary drivers when a 5-point or more increase occurred.<i>Conclusions:</i> Sudden 5-point or more increases in ALSFRS-R total scores between two consecutive visits are relatively common. These sudden increases were not found to occur with equal frequency in trial centers; which underscores the need for amending existing standard operating procedures toward a universal version and monitoring of data quality during the study, in multicentre research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bakers</LastName><ForeName>Jaap N E</ForeName><Initials>JNE</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Centre, University Medical Centre Utrecht, and De Hoogstraat Rehabilitation, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rehabilitation, Physical Therapy Science &amp;amp; Sports, UMC Utrecht Brain Centre, University Medical Centre Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jongh</LastName><ForeName>Adriaan D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bunte</LastName><ForeName>Tommy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kendall</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Biostatistics, GlaxoSmithKline R&amp;amp;D, Stevenage, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Steve S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Neurosciences, Takeda Pharmaceuticals, Cambridge, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epstein</LastName><ForeName>Noam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Discovery Medicine, GlaxoSmithKline R&amp;amp;D, Upper Providence, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavrov</LastName><ForeName>Arseniy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Development, Novartis Gene Therapies, Cambridge, UK, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beelen</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Centre, University Medical Centre Utrecht, and De Hoogstraat Rehabilitation, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rehabilitation, Physical Therapy Science &amp;amp; Sports, UMC Utrecht Brain Centre, University Medical Centre Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser-Meily</LastName><ForeName>Johanna M A</ForeName><Initials>JMA</Initials><AffiliationInfo><Affiliation>Centre of Excellence for Rehabilitation Medicine, UMC Utrecht Brain Centre, University Medical Centre Utrecht, and De Hoogstraat Rehabilitation, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rehabilitation, Physical Therapy Science &amp;amp; Sports, UMC Utrecht Brain Centre, University Medical Centre Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics &amp;amp; Research Support, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFRS-R</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">standard operating procedures</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>5</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34949141</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.2016838</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>